{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:53:59Z","timestamp":1792428839488,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Venous and arterial thromboembolism are prevalent, highly burdensome, and associated with risk of worse outcomes for patients with cancer. Risk for venous thromboembolism (VTE) varies widely across specific cancer subpopulations. The ability to predict risk of cancer-associated VTE is critical because an optimal thromboprophylaxis strategy is best achieved by targeting high-risk patients with cancer and avoiding prophylaxis in patients with cancer at low risk for VTE. A validated risk tool for solid tumors has been available for a decade. Newer tools have focused on specific populations, such as patients with multiple myeloma. Emerging studies continue to optimize risk prediction approaches in patients with cancer. Recent randomized trials have specifically addressed risk-adapted thromboprophylaxis using direct oral anticoagulants, and revised guidelines have included these new data to formulate recommendations for outpatient thromboprophylaxis. Implementation science approaches to enhance use of outpatient prophylaxis in the context of these guideline changes are under way. However, major knowledge gaps remain, including a lack of data for inpatient thromboprophylaxis in the cancer setting and a lack of formal tools for identifying risk of bleeding. This review describes optimal approaches to risk prediction and patient selection for primary pharmacologic thromboprophylaxis of cancer-associated VTE, addresses barriers to implementing these practices, and highlights strategies to overcome them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Risk for venous thromboembolism (VTE) varies widely among patients with cancer. Individual risk can be determined using validated approaches. Inpatient and postsurgical thromboprophylaxis is more widely accepted. However, most patients with cancer develop VTE in the outpatient setting. Recent randomized trials have demonstrated benefit to risk-adapted outpatient thromboprophylaxis. High-risk patients may therefore be considered for outpatient thromboprophylaxis as recommended by recently updated guidelines. System-wide implementation approaches are necessary to improve compliance with prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13569","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T08:42:42Z","timestamp":1607071362000},"page":"e2-e7","source":"Crossref","is-referenced-by-count":54,"title":["Prediction and Prevention of Cancer-Associated Thromboembolism"],"prefix":"10.1093","volume":"26","author":[{"given":"Alok A.","family":"Khorana","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"DeSancho","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Liebman","sequence":"additional","affiliation":[{"name":"Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rosovsky","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zwicker","sequence":"additional","affiliation":[{"name":"Division of Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"2021122511543928300_onco13569-bib-0001","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1538-7836.2003.00501.x","article-title":"Malignancy, thrombosis and Trousseau: The case for an eponym","volume":"1","author":"Khorana","year":"2003","journal-title":"J Thromb Haemost"},{"key":"2021122511543928300_onco13569-bib-0002","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: A single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"key":"2021122511543928300_onco13569-bib-0003","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - Choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"2021122511543928300_onco13569-bib-0004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2021122511543928300_onco13569-bib-0005","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1634\/theoncologist.2015-0361","article-title":"A validated risk score for venous thromboembolism is predictive of cancer progression and mortality","volume":"21","author":"Kuderer","year":"2016","journal-title":"The Oncologist"},{"key":"2021122511543928300_onco13569-bib-0006","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archinte.165.15.1782","article-title":"Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults","volume":"165","author":"White","year":"2005","journal-title":"Arch Intern Med"},{"key":"2021122511543928300_onco13569-bib-0007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.critrevonc.2017.08.003","article-title":"Mechanisms and risk factors of thrombosis in cancer","volume":"118","author":"Falanga","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122511543928300_onco13569-bib-0008","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122511543928300_onco13569-bib-0009","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"2021122511543928300_onco13569-bib-0010","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"2021122511543928300_onco13569-bib-0011","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"2021122511543928300_onco13569-bib-0012","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/jth.14139","article-title":"Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer","volume":"16","author":"Parker","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2021122511543928300_onco13569-bib-0013","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"key":"2021122511543928300_onco13569-bib-0014","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/S2352-3026(18)30067-X","article-title":"Simplicity versus complexity: An existential dilemma as risk tools evolve","volume":"5","author":"Khorana","year":"2018","journal-title":"Lancet Haematol"},{"key":"2021122511543928300_onco13569-bib-0015","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"2021122511543928300_onco13569-bib-0016","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: Development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"2021122511543928300_onco13569-bib-0017","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511543928300_onco13569-bib-0018","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"Brenner","year":"2018","journal-title":"Am J Med"},{"key":"2021122511543928300_onco13569-bib-0019","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122511543928300_onco13569-bib-0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolism preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"key":"2021122511543928300_onco13569-bib-0021","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival","volume":"113","author":"Ku","year":"2009","journal-title":"Blood"},{"key":"2021122511543928300_onco13569-bib-0022","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ajh.24130","article-title":"Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience","volume":"90","author":"Couturier","year":"2015","journal-title":"Am J Hematol"},{"key":"2021122511543928300_onco13569-bib-0023","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.2020006243","article-title":"Thrombosis in ALL: A risk without clear mitigation","volume":"136","author":"Stock","year":"2020","journal-title":"Blood"},{"key":"2021122511543928300_onco13569-bib-0024","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2016-02-701094","article-title":"Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia","volume":"128","author":"Libourel","year":"2016","journal-title":"Blood"},{"key":"2021122511543928300_onco13569-bib-0025","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"key":"2021122511543928300_onco13569-bib-0026","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.thromres.2015.08.002","article-title":"Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis","volume":"136","author":"Lustig","year":"2015","journal-title":"Thromb Res"},{"key":"2021122511543928300_onco13569-bib-0027","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511543928300_onco13569-bib-0028","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122511543928300_onco13569-bib-0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"key":"2021122511543928300_onco13569-bib-0030","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jth.14824","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis","volume":"18","author":"van Es","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021122511543928300_onco13569-bib-0031","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122511543928300_onco13569-bib-0032","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122511543928300_onco13569-bib-0033","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1055\/s-0040-1712143","article-title":"Assessing full benefit of rivaroxaban prophylaxis in high-risk ambulatory patients with cancer: Thromboembolic events in the randomized CASSINI trial","volume":"4","author":"Khorana","year":"2020","journal-title":"TH Open"},{"key":"2021122511543928300_onco13569-bib-0034","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/jth.14613","article-title":"Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis","volume":"17","author":"Li","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2021122511543928300_onco13569-bib-0035","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.32724","article-title":"Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"key":"2021122511543928300_onco13569-bib-0036","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2021122511543928300_onco13569-bib-0037","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122511543928300_onco13569-bib-0038","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ajh.24700","article-title":"Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool","volume":"92","author":"Patell","year":"2017","journal-title":"Am J Hematol"},{"key":"2021122511543928300_onco13569-bib-0039","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","article-title":"Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer","volume":"127","author":"Carrier","year":"2014","journal-title":"Am J Med"},{"key":"2021122511543928300_onco13569-bib-0040","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","article-title":"Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: A randomized, double-blinded multicenter phase 2 trial","volume":"4","author":"Zwicker","year":"2020","journal-title":"Blood Adv"},{"key":"2021122511543928300_onco13569-bib-0041","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1200\/JCO.2013.53.5336","article-title":"Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: A prospective, cross-sectional, multicenter study","volume":"32","author":"Zwicker","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122511543928300_onco13569-bib-0042","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/rth2.12176","article-title":"Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting","volume":"3","author":"Kunapareddy","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2021122511543928300_onco13569-bib-0043","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1200\/JOP.19.00697","article-title":"Successful model for guideline implementation to prevent cancer-associated thrombosis: Venous thromboembolism prevention in the ambulatory cancer clinic","volume":"16","author":"Holmes","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2021122511543928300_onco13569-bib-0044","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: The ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"The Oncologist"},{"key":"2021122511543928300_onco13569-bib-0045","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: The prospective COMPASS-Cancer-Associated Thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"The Oncologist"},{"key":"2021122511543928300_onco13569-bib-0046","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","article-title":"Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer","volume":"118","author":"Munoz Martin","year":"2018","journal-title":"Br J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13569","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13569","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/e2\/41923639\/oncolo_26_1_e2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/e2\/41923639\/oncolo_26_1_e2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T12:08:29Z","timestamp":1697285309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/1\/e2\/6445327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,4]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13569","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,12,4]]}}}